HIGHLIGHT
Evusheld

Evusheld

Manufacturer:

AstraZeneca

Distributor:

DKSH
Concise Prescribing Info
Contents
Tixagevimab, cilgavimab
Indications/Uses
Pre-exposure prophylaxis of COVID-19 & treatment of mild to moderate COVID-19 in adults & adolescents ≥12 yr weighing at least 40 kg.
Dosage/Direction for Use
IM Inj at different inj sites, preferably 1 in each of gluteal muscles. Adult & adolescent ≥12 yr weighing at least 40 kg Recommended dose: 600 mg (as 2 separate sequential inj of tixagevimab 300 mg & cilgavimab 300 mg). Prophylaxis May repeat dose once every 6 mth at the discretion of treating healthcare professional. Treatment Give as soon as possible after +ve viral test for SARS-CoV-2 & w/in 7 days after onset of symptoms.
Contraindications
History of severe hypersensitivity including anaphylaxis.
Special Precautions
Discontinue immediately if signs & symptoms of clinically significant hypersensitivity reaction or anaphylaxis occur. Thrombocytopenia or any coagulation disorder. Potential for breakthrough infections. Fever, cough, tiredness, loss of taste or smell, difficulty of breathing or shortness of breath, loss of speech or mobility, confusion & chest pain. Pregnancy & lactation. Not for use in paed <12 yr or weighing <40 kg.
Adverse Reactions
Hypersensitivity; inj site reaction.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J06BD03 - tixagevimab and cilgavimab ; Belongs to the class of antiviral monoclonal antibodies. Used in passive immunizations.
Presentation/Packing
Form
Evusheld soln for inj 150 mg/1.5 mL + 150 mg/1.5 mL
Packing/Price
2's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in